Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for Secondary Prevention of Chemotherapy-Induced Thrombocytopenia in NPC
NCT07252375Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of hetrombopag in Thrombocytopenia, sponsored by Fujian Medical University Cancer Hospital. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07252375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252375.